UPDATED SEPTEMBER 14, 2026
UPDATED SEPTEMBER 14, 2026

The Frontier

Your signal. Your price.

Include
Lookback
||
No Priors: Artificial Intelligence | Technology | Startups
  • · 3d ago

    Brian Armstrong states that traditional payment rails cannot support agentic commerce because 76% of AI agent transactions are under $0.30, while standard debit or credit card transactions impose a $0.30 flat fee minimum.

    +3 more
    +1 more
  • · 3d ago

    Brian Armstrong explains that Coinbase is banking AI agents via self-custodial wallets and crypto rails, bypassing traditional KYC identity requirements to let agents pay for API resources and digital goods.

    +3 more
    +2 more
  • · 3d ago

    Brian Armstrong predicts that the agentic economy will eventually surpass the human economy in size, as autonomous AI agents outnumber humans in the near future.

    +3 more
    +1 more
  • · 3d ago

    Brian Armstrong describes Coinbase's internal AI harness, Toshi, which achieves recursive self-improvement by writing human code review feedback back into repository-specific AI brains.

    +3 more
    +3 more
  • · 3d ago

    Brian Armstrong reports that 88% of Coinbase's revenue comes from non-Bitcoin trading, highlighting a structural shift toward a broader digital asset economy.

    +3 more
    +2 more
  • · 3d ago

    Brian Armstrong states that Coinbase launched a tokenized stock product outside the United States to target the 4 billion global individuals who lack access to traditional brokerage accounts.

    +3 more
    +2 more
  • · 3d ago

    Brian Armstrong states that Coinbase's prediction market product reached a $100 million revenue run rate within months of launching, growing at over 100% quarter-over-quarter.

    +3 more
    +2 more
  • · 3d ago

    Brian Armstrong co-founded New Limit to pursue epigenetic reprogramming, using machine learning to identify transcription factors that can restore youthful cell function without changing cell identity.

    +3 more
    +2 more
  • · 3d ago

    Brian Armstrong announces that New Limit has successfully reprogrammed a human cell type in animal models, with Phase 1 clinical trials for alcoholic liver disease launching next year.

    +3 more
    +2 more
  • · 3d ago

    Brian Armstrong estimates that New Limit's initial liver disease drug alone could address a $20 billion market, though the ultimate goal is systemic rejuvenation of healthy individuals.

    +3 more
    +2 more
  • · 3d ago

    Brian Armstrong notes that Pew Research data shows 80% of Americans support embryo editing for disease prevention, predicting that genetic screening will eventually become a standard parental safety practice.

    +3 more
    +1 more
  • · 3d ago

    Brian Armstrong advocates for the creation of special economic zones or freedom cities on US federal land to bypass restrictive regulations for testing experimental energy, drone, and medical technologies.

    +3 more
    +1 more
About The Frontier
End of 7-day results — 12 results
12 results